Lee, Vernon J; Phua, Kai Hong; Chenm, Mark I; Chow, Angela; Ma, Stefan; Goh, Kee Tai; Leo, Yee Sin; (2006) Economics of neuraminidase inhibitor stock piling for pandemic influenza, Singapore. Emerging infectious diseases, 12 (1). pp. 95-102. ISSN 1080-6040 DOI: https://doi.org/10.3201/eid1201.050556
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
We compared strategies for stock piling neuraminidase inhibitors to treat and prevent influenza in Singapore. Cost-benefit and cost-effectiveness analyses, with Monte Carlo simulations, were used to determine economic outcomes. A pandemic in a population of 4.2 million would result in an estimated 525-1,775 deaths, 10,700-38,600 hospitalization days, and economic costs of 0.7 dollars to 2.2 billion Singapore dollars. The treatment-only strategy had optimal economic benefits: stock piles of antiviral agents for 40% of the population would save an estimated 418 lives and 414 million dollars, at a cost of 52.6 million dollars per shelf-life cycle of the stock pile. Prophylaxis was economically beneficial in high-risk subpopulations, which account for 78% of deaths, and in pandemics in which the death rate was >0.6%. Prophylaxis for pandemics with a 5% case-fatality rate would save 50,000 lives and 81 billion dollars. These models can help policymakers weigh the options for pandemic planning.
Download
Filename: 05-0556.pdf
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0
Download